SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM S-8

             REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

                    Medical Technology and Innovations, Inc.
               (Exact Name of Registrant as Specified in Charter)


           Florida                 33-27610-A             65-2954561
 (State or Other Jurisdiction     (Commission           (IRS employer
      of Incorporation)           File Number)        Identification No.)


                               80 Abbeyville Road
                          Lancaster, Pennsylvania 17603
               (Address of principal executive offices) (Zip code)

               Registrant's telephone number, including area code:
                                  717-390-0352

                                2002 Stock Award
                            (Full title of the Plan)

                                  Eric Littman
                         1428 Brickell Avenue, 8th Floor
                              Miami, Florida 33131
                     (Name and address of agent for service)

                                  305-663-3333
          (Telephone number, including area code, of agent for service)

                             All Correspondence to:
                          Brenda Lee Hamilton, Esquire
                         Hamilton, Lehrer & Dargan, P.A.
                          2 East Camino Real, Suite 202
                            Boca Raton, Florida 33432
                            Telephone (561) 416-8956
                            Facsimile (561) 416-2855


                         CALCULATION OF REGISTRATION FEE
--------------------------------------------------------------------------------
Title of                                 Proposed          Proposed      Amount
Securities           Amount              Maximum           Maximum        of
to be                 to be           Offering Price      Aggregate       Fee
Registered         Registered (1)       per Share(2)    Offering Price
--------------------------------------------------------------------------------
Common Stock,      1,100,000              $ .07            $77,000       $7.08
No par value

TOTAL              1,100,000              $ .07            $77,000       $7.08
--------------------------------------------------------------------------------

(1) This Registration Statement shall also cover any additional shares of Common
Stock which become issuable under the Medical Technology and Innovations, Inc.
2002 Stock Award by reason of any stock dividend, stock split, recapitalization
or other similar transaction effected without the receipt of consideration which
results in an increase in the number of outstanding shares of common stock.

(2) This calculation is made solely for the purposes of determining the
registration fee pursuant to the provisions of Rule 457(c) under the Securities
Act of 1933, as amended, and is calculated on the basis of the average of the
high and low prices reported and last sale reported on the OTC Bulletin Board as
of September 17, 2002.

When used herein, the terms 'we,' 'us,' and 'our' refers to Medical Technology
and Innovations, Inc., a Florida corporation.

                                     PART I
                    INFORMATION REQUIRED IN THE SECTION 10(A)

ITEM 1.  INFORMATION
We will provide the information specified in Item 1 by Rule 428 of the
Securities Act of 1933 to each person receiving the shares registered hereunder.
We are not filing these documents as part of this registration statement or as
prospectuses or prospectus supplements, in accordance with the rules and
regulations of the Securities and Exchange Commission.

ITEM 2.  REGISTRANT INFORMATION AND EMPLOYEE ANNUAL INFORMATION
We will provide the information specified in Item 2 by Rule 428(b) of the
Securities Act of 1933 to each person receiving the shares registered hereunder.
We are not filing these documents as part of this registration statement or as
prospectuses or prospectus supplements, in accordance with the rules and
regulations of the Securities and Exchange Commission.

                                     PART II
               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3.  INCORPORATION OF DOCUMENTS BY REFERENCE
We incorporate by reference the documents, which we filed previously with the
Securities and Exchange Commission, listed below:
(a) Our Annual Report on Form 10-KSB for the year ended June 30, 2001, filed
with the Securities and Exchange Commission on September 28, 2001;
(b) Our Quarterly report on Form 10-Q, for the quarterly period ended
September 30, 2001, filed November 13, 2001;
(c) Our Quarterly report on Form 10-Q, for the quarterly period ended December
31, 2001, filed as February 14, 2002;
(d) Our Quarterly report on Form 10-Q for the quarter period ended March 31,
2002 filed as of May 15, 2002;
(d) Our Report on 8-K filed on December 19, 2001;
(e) Our Articles of Incorporation and any amendments thereto and Bylaws; and
(f) All other documents filed by us after the date of this registration
statement pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act,
prior to the filing of a post-effective amendment to this registration statement
which de-registers all securities then remaining unsold, shall be deemed to be
incorporated by reference in this registration statement and to be a part hereof
from the date of filing such documents.

ITEM 4.  DESCRIPTION OF SECURITIES
The following description is a summary and is qualified in its entirety by the
provisions of the Company's Articles of Incorporation and Bylaws, copies of
which have been filed as exhibits to the registration statement of which this
prospectus is a part.

COMMON STOCK
General. We are authorized to issue 28,000,000 shares of common stock no par
value. As of September 18, 2002, we had 5,502,602 shares of common stock issued
and outstanding. All shares of common stock outstanding are validly issued,
fully paid and non-assessable.

Voting Rights.
Each share of our common stock entitles the holder to one vote, either in person
or by proxy, at meetings of shareholders. The holders are not permitted to vote
their shares cumulatively. Accordingly, the holders of common stock holding, in
the aggregate, more than fifty percent (50%) of the total voting rights can
elect all of our directors and, in such event, the holders of the remaining
minority shares will not be able to elect any of such directors. The vote of the
holders of a majority of the issued and outstanding shares of common stock
entitled to vote thereon is sufficient to authorize, affirm, ratify or consent
to such act or action, except as otherwise provided by law.

Dividend Policy.
All shares of common stock are entitled to participate proportionally in
dividends if our Board of Directors declares them out of the funds legally
available and subordinate to the rights, if any, of the holders of outstanding
shares of preferred stock. These dividends may be paid in cash, property or
additional shares of common stock. Our Company has not paid any dividends in the
last two (2) years and presently anticipates that all earnings, if any, will be
retained for development of its business. Any future dividends will be at the
discretion of our Board of Directors and will depend upon, among other things,
our future earnings, operating and financial condition, capital requirements,
and other factors. Therefore, there can be no assurance that any dividends on
the common stock will be paid in the future.

Miscellaneous Rights and Provisions.
Holders of our common stock have no preemptive or other subscription rights,
conversion rights, redemption or sinking fund provisions. In the event of our
dissolution, whether voluntary or involuntary, each share of common stock is
entitled to share proportionally in any assets available for distribution to
holders of our equity after satisfaction of all liabilities and payment of the
applicable liquidation preference of any outstanding shares of preferred stock.

PREFERRED STOCK
We are authorized to issue One Hundred Million (100,000,000) shares of preferred
stock which shall have a par value of $1,000.

The designations, powers, preferences, rights, and the qualifications,
limitations or Restrictions of the authorized undesignated Common Stock and
Preferred Stock are as follows:

a.  One Hundred (100) shares of Preferred Stock with a $1,000 par value
(hereinafter "the 12% Preferred Stock") shall be entitled to a 12% noncumulative
dividend. The 12% Preferred Stock shall be preferenced as liquidation and return
of capital up to its par value. The Corporation may upon fifteen (15) days
notice, redeem any or all of the 12% Preferred Stock by paying the full par
value together with any accrued dividend legally due. The 12% Preferred Stock
shall be entitled to two (2) votes per share. The 12% Preferred Stock is
convertible at the option of the holder for 666 shares of the Corporation's
Common Stock for each share of Preferred Stock.

b.  The Board of Directors is expressly authorized at any time to provide for the
Issuance of shares of any undesignated and authorized stock in one or more
series, with such voting powers full or limited but may not exceed five (5)
votes per share, or without voting powers and with such designations,
preferences, relative participating, optional or other special rights, and
qualifications, limitations or restrictions thereof, as shall be expressed in
the resolution or resolutions providing for the issue thereof adopted by the
Board of Directors and as are not expressed in this Articles of Incorporation or
any amendment thereto, including (but not limiting the generality of the
foregoing) the following:
i.  the destination of the series;
ii. the dividend rate of such series, the conditions and dates upon which such
dividends shall be payable, the preference or relation which such dividends
shall bear to the dividends payable on any other class or classes or on any
series of any class or classes of authorized stock of the Corporation, and
whether such dividends shall be cumulative or noncumulative;
iii  whether the shares of such series shall be subject to redemption by the
Corporation, and, if made subject to such redemption, the times, prices and
other terms and conditions of such redemption;
iv. the terms of any sinking fund provided for the purchase or redemption of the
shares of the series;
v.  whether the shares of such series shall be convertible into or exchangeable
for shares of any other class or classes of any other series or any class or
classes of authorized stock of the Corporation, and, if provision be made for
conversion or exchange, the times, prices, rates, adjustments, and other terms
and conditions of such conversion or exchange;
vi. the extent, if any, to which the holders of the shares of such series shall
be entitled to vote as a class or otherwise with respect to the election of
Directors or otherwise; provided, however, that in no event shall any holder of
any series of Preferred Stock be entitled to more than two (2) votes for each
share of such Preferred Stock held by him;
vii. the restrictions and conditions, if any, upon the issue or reissue of any
additional Preferred Stock ranking on a parity with or prior to such dividends
or upon dissolution;
viii. the rights of the holders of the shares of such series upon the
dissolution of, upon the distribution upon the dissolution of, or upon the
distribution of assets of, the Corporation, which rights may be different in the
case of a voluntary dissolution than in the case of an involuntary dissolution.
Except as otherwise required by law and except for such voting powers with
respect to the election of Directors or other matters as may be stated in the
resolutions of the Board of Directors creating any series of Common or Preferred
Stock, the holders of such series shall have no voting power whatsoever.

ITEM 5.  INTERESTS OF NAMED EXPERTS AND COUNSEL
Hamilton, Lehrer and Dargan, P.A. will review the validity of the issuance of
the shares of our common stock being offered. They are located at 2 East Camino
Real, Suite 202, Boca Raton, Florida 33432. Members of the law firm of Hamilton,
Lehrer and Dargan, P.A. own 100,000 shares of our common stock which are being
registered hereunder.

Our financial statements have been audited by SIMON LEVER & COMPANY, Certified
Public Accountants, as set forth in their report incorporated herein by
reference, and are incorporated herein in reliance upon the authority of said
firm as experts in auditing and accounting.

ITEM 6.  INDEMNIFICATION OF OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS
Not applicable.

ITEM 7.  EXEMPTION FROM REGISTRATION CLAIMED
Not applicable.

ITEM 8.  EXHIBITS
a)  The following exhibits are filed as part of this registration statement
pursuant to Item 601 of the Regulation S-B and are specifically incorporated
herein by this reference:

Exhibit No.                Title

   5.1     Legal opinion of Hamilton, Lehrer & Dargan, P.A.
   5.2     Consent of Hamilton, Lehrer & Dargan, P.A. (contained in Exhibit 5.1)
  10.1     Agreement with James Howson
  10.2     Agreement with Brenda Lee Hamilton, Esquire
  23.2     Consent of SIMON LEVER & COMPANY, Certified Public Accountants

ITEM 9.  UNDERTAKINGS
We hereby undertake:
1)    To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i)   To include any prospectus required by section 10(a)(3) of the Securities
Act of 1933;
(ii)  To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
changes in volume and price represents no more than a twenty percent (20%)
change in the maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement;
(iii) To include any material information with respect to the distribution
not previously disclosed in the registration statement or any material change to
such information in the registration statement, provided, however, that
paragraphs (1)(i) and (1)(ii) do not apply if the registration statement is on
Form S-3 or Form S-8 and the information required to be included in a
post-effective amendment by those paragraphs is contained in periodic reports
filed by the Corporation pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.

(2)   That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.

(3)   To remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of the
offering.

Medical Technology and Innovations, Inc. hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of its
annual report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit's annual report pursuant to Section 15(d) of the Securities Exchange Act
of 1934) that is incorporated by reference in the registration statement shall
be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act of
1933 may be permitted to directors, officers, and controlling persons of Medical
Technology and Innovations pursuant to the foregoing provisions, or otherwise,
Medical Technology and Innovations, Inc. has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by Medical Technology and Innovations, Inc. of expenses incurred or paid
by a director, officer or controlling person of Medical Technology and
Innovations, Inc. in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with
the securities being registered, Medical Technology and Innovations, Inc. will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.

                                   SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, Medical Technology
and Innovations, Inc. certifies it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-8 and has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized in the city of Lancaster, State of Pennsylvania, on September
18, 2002.

Medical Technology and Innovations, Inc.
(Registrant)

/s/ Jeremy Feakins
---------------------
    Jeremy Feakins,
    Chief Executive Officer, Sole Director